GAJ - HIV DART 2010 Presentations






		HIV DART 2010 Frontiers in Drug Development for Antiretroviral Therapies Click here to view the complete abstract book Selected Slide Presentations Click on the links below to view presentations. Reservoirs, Persistence and Eradication Gertrude Elion Distinguished Lecturer Award Lecture: Persistence, Resistance, Diversity: Insights into the HIV-host Interaction John Coffin; Tufts University, USA Prospects for HIV Eradication Sharon Lewin; Alfred Hospital, Australia Immunotherapies The PD-1 Inhibitory Co-signaling Pathway in HIV Infection and the Potential for Therapeutic Intervention Daniel Kaufmann; Harvard University, USA Lentiviral Vectors as HIV Vaccine Candidates: A Highly Immunogenic Lentiviral Vaccine Provides Control of Viral Load, Preservation of the CD4 Compartment, and Survival Advantage Post-SIV Challenge Franck Lemiale; VIRxSYS Corporation, USA Viral Hepatitis Co-infection and Other HIV Co-morbidities State of the Art Lecture: Liver Disease and Therapy of Hepatitis B Virus Infection in HIV Infected Persons William Mason; Fox Chase Cancer Center, USA Co-infection with Hepatitis B Marion Peters; University of California, San Francisco, USA Malignancies in HIV: A Growing Problem Ronald Mitsuyasu; University of California, Los Angeles, USA Antiretroviral Targets David Barry DART Achievement Award Lecture: Pharmacokinetic Boosting: A Paradigm Shift in Antiviral Therapy Dale Kempf; Abbott Laboratories, USA Discovery of Novel Inhibitors of HIV-1 Reverse Transcriptase by Crystallographic Fragment Screening Eddy Arnold; Rutgers University, USA Small Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization Christopher Aiken; Vanderbilt University, USA Treatment Strategies in Developing Countries Infant HAART in Resource Limited Countries Annelies Van Rie; University of North Carolina Chapel Hill, USA Differences between HIV Subtypes in Development of Drug Resistance: The Clustering of Transmitted Resistance Mark Wainberg; McGill AIDS Center, Canada The Impact of CMV-associated Inflammation on HIV Disease Outcomes Steven Deeks; University of California, San Francisco, USA Inflammation, Pharmacology, Toxicology and Drug Metabolism State of the Art Lecture: Lipodystrophy and Metabolic Toxicity of Antiretroviral Therapy David Cooper; University of New South Wales National Centre in HIV Epidemiology & Clinical Research, Australia Chronic Inflammation and Medical Complications in HIV David Shepp; Hofstra University School of Medicine, North Shore University Hospital, USA HIV, Inflammation, and Cardiovascular Disease Laurence Sperling; Emory University School of Medicine, USA Preventing Transmission: Microbicides and Other Approaches State of the Art Lecture: Treatment as Prevention: Five Year Experience in British Columbia, Canada Julio Montaner; BC Centre for Excellence in HIV/AIDS, Canada A Pill a Day to Keep HIV Away Robert Grant; Gladstone/UCSF, USA Sex is Messy Davey Smith; University of California, San Diego, USA Novel Monitoring and Diagnostic Approaches Predicting HIV Response to Antiretroviral Therapy Daniel Kuritzkes; Brigham and Women?s Hospital, USA Special Lecture: Emerging Retroviruses: XMRV: The Link to Prostate Cancer and Chronic Fatigue Syndrome Ila Singh; University of Utah, USA Oral Abstract Presentations DermaVir Therapeutic HIV Vaccine: Phase I and II Clinical Data in ARV Treated and Naïve HIV+ Subjects Julianna Lisziewicz; Genetic Immunity, Hungary The Preclinical and Clinical Chemokine Receptor 2 (CCR2) Activity of TBR 652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection Richard Ogden; Tobira Therapeutics, Inc., USA Development of a Cellular Immunotherapy for ART Naïve Patients for the Purpose of Delaying or Preventing Initiation of ART Charles Nicolette; Argos Therapeutics, Inc., USA AIC246, a Potent Novel, Well Tolerated Non-Nucleosidic Compound Against Human Cytomegalovirus (HCMV) with Resistance Breaking Potential Helga Rübsamen-Schaeff; AiCuris, Germany Homing Endonucleases for the Targeted Disruption of Integrated HIV Keith Jerome; Fred Hutchinson Cancer Research Center, and University of Washington, USA 12 Week Analysis of the SENSE Trial: Etravirine versus Efavirenz in Treatment-naïve Patients Mark Nelson; Chelsea and Westminster Hospital, UK CMX157 (Hexadecyloxypropyl Tenofovir), a Clinical Stage Antiretroviral with Activity against HIV and XMRV Randall Lanier; Chimerix Inc., USA Anti-HIV Effect In Vitro of Human Milk Glycosaminoglycans Monica Viveros-Rogel; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico Pooled Week 48 Efficacy and Safety Results from ECHO and THRIVE, Two Double-blind, Randomized, Phase III Trials Comparing TMC278 versus Efavirenz in Treatment-naïve, HIV-1-infected Patients Katia Boven; Tibotec Inc., USA HIV DART 2010 Satellite Mini-symposium: Brighter Future of HIV Therapeutics December 7, 2010 Welcome and Overview Talk: New Drugs for HIV and Combinations Robert Murphy; Northwestern University, USA Integrase Inhibitors: Past, Present and Future Daria Hazuda; Merck Research Laboratories, USA The Clinical Implications of HIV Persistence during Therapy Tom North; Emory University, USA